Skip to main content

Table 5 Change in fasting plasma glucose, HbA1c and insulin sensitivity indices from baseline with treatment

From: Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study

Parameters* Mean (SD)

Baseline

Week 13

Week 27

Absolute change from baseline to week 27

FPG (mmol/L)

13.1 (1.1)

11.7 (1.1)

9.8 (0.6)

3.2 (0.7)

HbA1c (%)

9.5 (1.3)

9.3 (1.1)

9.3 (1.1)

-0.2 (0.9)

HOMA-IR

27.1 (6.8)

28.6 (16.5)

22.3 (7.7)

-4.0 (0.7)

ADIPO-IR

470.3 (114.3)

385.8 (230.9)

216.3 (70.6)

-209.3 (120.4)

ISI

0.045 (0.007)

0.039 (0.004)

0.037 (0.001)

-0.0039 (0.002)